Article ViewAbstractThe Review of Diabetic Studies,2006,3,4,208-216.DOI:10.1900/RDS.2006.3.208Published:February 2007Type:Diabetic PerspectivesAuthors:Baptist Gallwitz Author(s) affiliations:Baptist Gallwitz Medizinische Klinik IV, Universitätsklinikum Tübingen, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. Abstract:This article gives an overview of two recent trials investigating rosiglitazone, a thiazolidinedione, in its potential to prevent type 2 diabetes (T2D) and in its effectiveness in monotherapy. Thiazolidinediones are among the most important developments of recent years for combating T2D and therefore worth to revisit. The possible influence of thiazolidines in improving beta-cell function is discussed as well as the potential effects on insulin resistance and obesity. Novel, incretin-based therapies (GLP-1 analogues and DPP-4 inhibitors) and their effects on beta-cell function and beta-cell mass are also summarized and critically evaluated. Keywords:Beta-cell function, Beta-cell mass, DPP-4 inhibitors, Incretin mimetics, Rosiglitazone, Thizolidinediones, Type 2 diabetesView:PDF (423.2 KB) PDFClick here to download the PDF file. Images Immunohistochemical analysis of pancreatic sections of HFD/STZdiabetic mice treated with vehicle or des-fluoro-sitagliptin ‹ Maternally Inherited Diabetes with Deafness and Obesity: Body Weight Reduction Response to Treatment with Insulin Analogues up